BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
SUBSCRIBE
BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
BullScope
No Result
View All Result
Home Bargains & Bubbles

Coca-Cola: The Filed Numbers Show a Business Earning More Per Dollar, While the Market Prices in Perfection

Moe Alsumidaie by Moe Alsumidaie
July 21, 2026
in Bargains & Bubbles
0
75
SHARES
1.2k
VIEWS
Share on XShare on LinkedInShare on Facebook

Coca-Cola’s net revenue grew strongly in the first quarter of 2026, the strongest reported top-line gain in years, according to the Q1 2026 earnings release. What makes that number worth examining is not its size but its composition: volume and price both moved in the same direction at the same time, which is rarer than it sounds for a company selling sugary drinks in a cost-conscious world.

The 90-second Evidence Brief version of this article. Presented by an AI avatar of the author; every figure verified against the filings.

In one breath

The filed numbers show Coca-Cola growing both the amount it sells and what it charges per unit, while its profit margin per dollar of revenue is at a decade high. The stock is priced at a level that, measured against sales, sits near the top of its own ten-year range. The open question is whether the business can sustain the kind of balanced growth the first quarter showed, or whether one of those two engines, volume or price, stalls before the market’s expectations catch up with reality.

What the filings actually show

Start with the margin story, because it is the quieter and more durable piece of evidence. Our data, computed from SEC filings, show that Coca-Cola’s net margin in full-year 2025 reached 27.3%, the highest in the five-year window we track. To put that in graspable terms: for every dollar of revenue the company collected last year, it kept about 27 cents as profit after all costs. In 2022, that figure was closer to 22 cents. The improvement is not dramatic quarter to quarter, but compounded over three years it represents a meaningfully different business than the one investors were buying in 2022.

The Q1 2026 earnings release adds texture to that trend. Gross margin, the share of each sales dollar left after the direct cost of making the product, came in above 63% for the quarter, up slightly from the prior-year period. That gain matters because it happened while the company was also growing volume, which typically pressures margins as more concentrate moves through the system at fixed promotional costs. Holding margin while growing volume is the combination a consumer-staples business wants to show.

BullScope TerminalCoca-Cola was the article. The engine is the product.Same yardsticks, any ticker: filed financials in, math-vs-mood out. Nothing here is advice; it is the evidence, organized.Run another company →

Revenue growth itself tells a story of transition. Annual revenue gains decelerated sharply from 2021 through 2024 and 2025. The Q1 2026 jump to 12% total revenue growth looks like an acceleration, though the company’s own Q1 release notes that concentrate sales ran well ahead of unit case volume partly because the quarter had six additional calendar days. Strip that calendar effect out and the underlying trend is more moderate, which is worth holding in mind before treating one quarter as a new trajectory.

Volume and price: the two engines

Organic revenue, a non-GAAP figure that strips out currency swings and acquisitions to show what the core business actually did, grew 10% in Q1 2026. That growth came from two sources: a strong rise in concentrate sales and a smaller contribution from price and mix. Unit case volume, the actual number of eight-ounce servings sold globally, grew 3%.

The price-and-mix line deserves a plain-language translation. “Price/mix” means the combined effect of charging more per unit and selling a higher proportion of premium products. Think of a coffee shop that raises its latte price by 50 cents and also sells more large sizes: both moves lift revenue without selling a single extra cup. For Coca-Cola in Q1 2026, pricing actions added several percentage points to that metric, but an unfavorable mix, meaning consumers leaning toward cheaper pack sizes or markets, partially offset those gains, per the Q1 2026 earnings call transcript. The net result was a modest but positive price contribution alongside genuine volume growth.

North America posted 4% volume growth in the quarter. Latin America grew despite a new sugar tax in Mexico, which is a meaningful stress test of brand loyalty. Asia Pacific expanded across all operating units. For a business of this scale, broad-based volume growth is the filed evidence that consumers are still choosing the product rather than trading down, and that matters to anyone assessing whether the margin story can hold.

What the market is paying

The stock has risen roughly a fifth over the prior twelve months and sits near its 52-week high. The market is paying about 27 times earnings, which our published methodology shows sits near the middle of Coca-Cola’s own decade range. That reading sounds reasonable until the price-to-sales multiple enters the picture.

BullScope TerminalWant the full evidence sheet behind pieces like this?The terminal runs the complete workup: Coca-Cola and 500+ other names, on the same official data.See the evidence engine →

The price-to-sales ratio, which is simply the total market value of the company divided by its annual revenue, sits at 7.5 times. Our data show the decade median for Coca-Cola is 6.6 times, placing the current reading at the 94th percentile of its own history. In plain terms: investors have paid this much relative to Coca-Cola’s revenue only about 6% of the time over the past decade. The mood, what the market is currently paying, is running well ahead of where it has historically settled.

The divergence between the earnings multiple sitting near its median and the sales multiple sitting near its ceiling has a logical explanation. Margins have expanded, so the same dollar of revenue now produces more profit than it used to, making the earnings multiple look more normal than the sales multiple. But that also means the stock’s current valuation assumes those elevated margins persist. A reversion toward the net margins of 2022 to 2023 would make the earnings multiple look considerably less comfortable at today’s price.

Where math and mood disagree

The math, what the filed fundamentals show, describes a business that has quietly become more profitable per dollar of revenue while also returning to genuine volume growth. That is a better combination than most large consumer-staples companies have managed in the post-pandemic period.

The mood, what the market is paying, reflects that improvement and then some. The sales multiple near a decade high means investors are not just paying for current profitability; they are paying for the expectation that the margin expansion holds and that volume growth continues at a pace the company’s own full-year guidance frames more modestly, at 4% to 5% organic revenue growth for all of 2026.

The strongest bull reading is that the margin improvement is structural, driven by portfolio mix and pricing discipline, and that even moderate volume growth sustains the earnings power the market is pricing. The strongest bear reading is that Q1’s strong total revenue gain was flattered by calendar timing, that the sugar tax in Mexico and similar pressures in other markets represent a gathering headwind to volume, and that any margin compression from input costs or promotional spending would leave the stock’s sales multiple looking exposed. Both readings are consistent with the filed evidence. The data do not resolve the disagreement; they define it.

BullScope TerminalYou just read Coca-Cola’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →

The next piece of evidence arrives July 28, 2026, when Coca-Cola reports Q2 2026 results before the New York Stock Exchange opens. The Q2 figures will show whether the volume growth was broad and durable or concentrated in the calendar-aided Q1, and whether gross margin held without the tailwind of extra selling days. Those two data points will do more to resolve the math-versus-mood tension than anything else available before then.

Reading the numbers

27.3% net margin (full-year 2025, our data from SEC filings). Net margin is what a company keeps from each dollar of revenue after every cost, tax, and interest payment is settled. For Coca-Cola in 2025, that was about 27 cents per dollar, up from roughly 22 cents in 2022. Think of a food stall that used to clear $22 profit on every $100 in sales and now clears $27. The stall hasn’t grown much faster, but it’s meaningfully more valuable per dollar it brings in. This matters here because it explains why the earnings multiple looks moderate even as the sales multiple sits near a decade high: the same revenue now generates more profit than it used to.

3% unit case volume growth (Q1 2026, Q1 2026 earnings release). Unit case volume counts the actual physical servings sold, standardized to eight-ounce equivalents, across every market Coca-Cola operates in. A 3% gain means roughly three more servings sold for every hundred sold a year earlier. That sounds small, but for a company already selling billions of servings a day, it signals that consumers are buying more of the product rather than the company simply charging more for the same amount. Volume growth and price growth happening together is the combination the filed numbers show for Q1 2026, and it’s the combination the market’s current valuation appears to be pricing as the new normal.

7.5 times price-to-sales, at the 94th percentile of the decade range (our published methodology). The price-to-sales ratio tells an investor how many dollars the market charges per dollar of annual revenue. A household analogy: if a rental property generates $20,000 a year in rent and someone offers to buy it for $150,000, the price-to-sales ratio is 7.5. Coca-Cola’s decade median is 6.6 times, meaning investors have historically paid about $6.60 for every dollar of the company’s annual sales. At 7.5 times today, they are paying more than at roughly 94 out of every 100 historical observations. That premium is defensible if margins stay elevated. It becomes harder to defend if margins revert toward their recent historical range.

For the standing yardsticks on Coca Cola — the price tag, the filed record, and the four gauges, refreshed with each edition — see the BullScope Evidence Sheet: Coca Cola.

Sources

  • Coca-Cola Q1 2026 earnings release, April 28, 2026
  • Coca-Cola Q2 2026 earnings timing announcement
  • Coca-Cola Q1 2026 earnings call transcript, Motley Fool, April 28, 2026
  • TIKR: Coca-Cola raises full-year guidance after Q1 results
  • TradingView: Coca-Cola Q1 2026 revenue and operating income summary
  • Hudson Labs: Coca-Cola Q2 2026 earnings preview
BullScope publishes impersonal research for a general audience. Nothing here is personalized investment advice, and nothing here is a recommendation to buy or sell any security. As of publication, neither BullScope nor its operator holds a position in any security, covered or otherwise; we do not trade at all, and we accept no compensation from any company we cover. When a conflict of interest exists, we do not publish: companies that compensate our operator in any capacity, or about which our operator could hold nonpublic information, are barred from coverage automatically, as described in the conflicts policy in our methodology. Figures come from company filings and public data through our published methodology; forecasts are conditional scenarios, not predictions and not promises. Markets carry risk, including loss of principal. Consider your own situation, or consult a licensed adviser, before acting on anything you read.
BullScope TerminalYou just read Coca-Cola’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →
Moe Alsumidaie

Moe Alsumidaie

Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.

Recommended For You

Abbott’s Split Personality: Revenue Climbs 14%, the Stock Falls Anyway

by Moe Alsumidaie
October 22, 2026
0

Abbott Laboratories spent most of the pandemic era as a Wall Street darling, its COVID test sales turning a steady healthcare conglomerate into a growth story. Then the...

Read moreDetails

The $14 Acquisition Price and the Arbitrage Gap the Market Is Pricing

by Moe Alsumidaie
October 16, 2026
0

The short version Sun Pharmaceutical agreed in April 2026 to buy Organon for $14.00 a share in cash, a deal Organon shareholders approved in July. The stock trades...

Read moreDetails

From $8 to $0.45: Ascend Wellness Is Generating Real Cash While the Market Prices It for Failure

by Moe Alsumidaie
October 14, 2026
0

The story, briefly The math, meaning what the filed numbers actually show, tells a story of a cannabis retailer that turned cash-flow positive in 2023 and has been...

Read moreDetails

ADMA Biologics: A Business Earning Real Money, Priced Like It Might Not

by Moe Alsumidaie
October 13, 2026
0

Six years ago, ADMA Biologics was losing nearly two dollars for every dollar it brought in. The company made a single class of medicine, plasma-derived immunoglobulins (proteins collected...

Read moreDetails

Viatris: The Stock Has Run 72% in a Year. The Filed Numbers Tell a More Complicated Story.

by Moe Alsumidaie
October 9, 2026
0

The share price is up 72% over the past twelve months. Revenue has fallen every single year since 2021. Those two facts belong to the same company, and...

Read moreDetails
Next Post

Hiring Slowed, Prices Cooled, and the Fed Held Steady: What June's Numbers Mean for Earnings Season

Please login to join discussion
BullScope
The Research Terminal
Run any stock through the BullScope evidence engine. Filings in, evidence out. Every number explains itself.
Open the Terminal
A BullScope product

Related News

A $2.4 Billion Question: What Sarepta’s Filed Numbers Actually Say

September 3, 2026
NVIDIA at the cheap end of its own decade: when the math outgrows the mood

NVIDIA at the cheap end of its own decade: when the math outgrows the mood

July 30, 2026

Three FDA Clocks, One Burning Balance Sheet: What BridgeBio’s Latest Filing Actually Shows

October 13, 2026
BullScope

BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.

Prefer BullScope.ai on Google

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

No Result
View All Result
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

Not enough quota to unlock this post
Unlock left : 0
Are you sure want to cancel subscription?
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.